Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 5, 2009, Pages 773-777

  Ikeda, Masahiko ^a   Kurebayashi, Junichi ^a   Sonoo, Hiroshi ^a   Oota, Yusuke ^a   Fujii, Sayaka ^a   Shimo, Toshirou ^a   Miyake, Akiko ^a   Seki, Mari ^a   Souda, Mai ^a   Nomura, Tsunehisa ^a   Yamamoto, Yutaka ^a   Shiiki, Shigeo ^a   Nakashima, Kazutaka ^a   Tanaka, Katsuhiro ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Irinotecan hydrochloride (CPT 11); Metastatic breast cancer; Trastuzumab

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IRINOTECAN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; HOSPITAL PATIENT; HUMAN; NAUSEA; NEUTROPENIA; OUTPATIENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE;

EID: 79959840932     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Therasse P, Arbuck E, Wanders J, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3): 205-216, 2000. (Pubitemid 30099779)
2. Jacobs TW, Gown AM, Yaziji H, et al: Specificity of HercepTest in determining HER-2/neu status of breast cancer using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17: 1983-1987, 1999.
3. Hortobagyi GN: Drug therapy: treatment of metastatic breast cancer. N Engl J Med 339(14): 974-984, 1998.
4. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11): 783-792, 2001. (Pubitemid 32222155)
5. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23(19): 4247-4250, 2005.
6. Burstein HJ, Harris LN, Marcom PK, et al: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21(15): 2889-2895, 2003. (Pubitemid 46621838)
7. Bartsch R, Wenzel C, Altorjai G, et al: Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25(25): 3853-3858, 2007. (Pubitemid 47477260)
8. Yamamoto D, Iwase S, Kitamura K, et al: A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer Chemother Pharmacol 61(3): 509-514, 2008. (Pubitemid 350275987)
9. Doihara H, Takashima S and Yokoyama N: Four cases of recurrent breast cancer effectively treated by the new antitumor agent, CPT-11 (irinotecan). Gan To Kagaku Ryoho 21(8): 1263-1266, 1994. (Pubitemid 24248047)
10. Shigeoka Y, Itoh K, Igarashi T, et al: Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens. Jpn J Clin Oncol 31: 370-374, 2001. (Pubitemid 32958588)
11. Okubo S, Kurebayashi J, Sonoo H, et al: Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer. Gan To Kagaku Ryoho 30(10): 1441-1445, 2003.
12. Perez EA, Hillman DW, Mailliard JA, et al: Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22(14): 2849-2855, 2004. (Pubitemid 41079903)
13. Burris HA 3rd, Hurwitz HI, Dees EC, et al: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23(23): 5305-5313, 2005. (Pubitemid 46206984)
14. Burstein HJ, Storniolo AM, Franco S, et al: A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008 Feb 17. [Epub ahead of print].